• Capricor Therapeutics (CAPR) Upgraded to “Hold” by Zacks Investment Research

    Zacks Investment Research upgraded shares of Capricor Therapeutics (NASDAQ:CAPR) from a sell rating to a hold rating in a report published on …

    Read More
  • 0 0